Clinical data | |
---|---|
Trade names | Paludrine, others |
Other names | chlorguanide, chloroguanide[1] |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Protein binding | 75% |
Metabolism | By liver (CYP2C19) |
Metabolites | cycloguanil and 4-chlorophenylbiguanide |
Elimination half-life | 12–21 hours[2] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.007.196 |
Chemical and physical data | |
Formula | C11H16ClN5 |
Molar mass | 253.73 g·mol−1 |
3D model (JSmol) | |
Melting point | 129 °C (264 °F) |
| |
| |
(verify) |
Proguanil, also known as chlorguanide and chloroguanide, is a medication used to treat and prevent malaria.[3][4] It is often used together with chloroquine or atovaquone.[4][3] When used with chloroquine the combination will treat mild chloroquine resistant malaria.[3] It is taken by mouth.[4]
Side effects include diarrhea, constipation, skin rashes, hair loss, and itchiness.[3] Because malaria tends to be more severe in pregnancy, the benefit typically outweighs the risk.[3] If used during pregnancy it should be taken with folate.[3] It is likely safe for use during breastfeeding.[3] Proguanil is converted by the liver to its active metabolite, cycloguanil.[4]
It is on the World Health Organization's List of Essential Medicines.[5] In the United States and Canada it is only available in combination as atovaquone/proguanil.[6]